The dysmenorrhea treatment market is expected to register a CAGR of 8.1% during the forecast period. Dysmenorrhea, also known as menstrual cramps, is cramping or throbbing pains in the lower abdomen. Most of the women experience dysmenorrhea just before and during their menstrual periods. Dysmenorrhea is of two types, namely primary and secondary dysmenorrhea. Prostaglandin-induced uterine contractions cause primary dysmenorrhea and secondary dysmenorrhea means pelvic pain caused by (secondary to) a disorder or disease.
Dysmenorrhea can create complications such as endometriosis that can cause fertility problems, increasing the risk of a fertilized egg implanting outside of the uterus (ectopic pregnancy), and pelvic inflammatory disease can scar fallopian tubes.
As per the study published in the International Journal of Gynecology & Obstetrics, dysmenorrhea affects more than 80% of women in the reproductive age, and it is the most common gynecological problem worldwide.
Increasing incidence and prevalence of dysmenorrhea and growing awareness regarding dysmenorrhea among females and increasing research and development by companies for developing innovative drugs are the key driving factors in the dysmenorrhea treatment market.
Get a PDF Sample for more detailed market insights: https://www.sdki.jp/sample-request-89228
Key Market Trends
Non-Steroidal Anti-Inflammatory Drugs Segment is Expected to Hold a Major Market Share in the Dysmenorrhea Treatment Market
– Some of the US Food and Drug Administration (FDA) approved NSAIDs for treatment of dysmenorrhea are diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen.
– According to the Women’s Health Concern and British Menopause Society, about 80% of dysmenorrhea women experience period pain at some stage in their lifetime. Most women experience some discomfort during menstruation, especially on the first day. But in 5%-10% of women, the pain is severe enough to disrupt their life.
– Moreover, the prevalence of diseases such as endometriosis, which is the leading cause of secondary dysmenorrhea, is also globally.
– Non-steroidal anti-inflammatory drugs segment holds a significant market share in the dysmenorrhea treatment market. It is anticipated to show a similar trend over the forecast period due to highly effective relieving pain, lower cost, and easy availability of products.
Dysmenorrhea Treatment Market
Onychomycosis Treatment Market
Kinesio Tape Market
Digital PCR Market
Cholesterol Testing Products and Services Market
Infection Control Market
Hepatorenal Syndrome Treatment Market
Osteonecrosis Treatment Market
Contact Lens Solution Market